Guggenheim Maintains Buy on Monte Rosa Therapeutics, Lowers Price Target to $30

Benzinga Newsdesk www.benzinga.com Negative 52.6%

Neg 52.6% Neu 0% Pos 0%

Guggenheim analyst Michael Schmidt maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and lowers the price target from $34 to $30.